Coherus Oncology, INC. (CHRS) — SEC Filings

Overview

Coherus Oncology, INC. (CHRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 20, 2026: Coherus Oncology, Inc. filed its Annual Report to Security Holders (ARS) on April 20, 2026, for the period ending December 31, 2025. The report details the company's performance and financial standing for the fiscal year 2025. The filing was made with the SEC under accession number 0001104659-26-045

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Coherus Oncology, INC. is neutral.

Filing Type Overview

Coherus Oncology, INC. (CHRS) has filed 1 ARS, 26 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 DEFA14A, 1 SC 13G, 7 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Coherus Oncology Files 2025 Annual Report — ARS · Apr 20, 2026 Risk: low
  Coherus Oncology, Inc. filed its Annual Report to Security Holders (ARS) on April 20, 2026, for the period ending December 31, 2025. The report details the comp
• Coherus Oncology Files 8-K with Financial Data — 8-K · Nov 13, 2025 Risk: low
  On November 13, 2025, Coherus Oncology, Inc. filed an 8-K report. The filing indicates historical financial data, including details on additional paid-in capita
• Coherus Swings to Profit on UDENYCA Divestiture, LOQTORZI Sales Up — 10-Q · Nov 6, 2025 Risk: medium
  Coherus Oncology, Inc. reported a net income of $205.667 million for the nine months ended September 30, 2025, a significant increase from $79.203 million in th
• Daiichi Sankyo to Acquire Coherus Oncology — 8-K · Sep 8, 2025 Risk: medium
  Coherus Oncology, Inc. announced on September 5, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company,
• Coherus Oncology Revenue Surges 209% on Toripalimab Sales — 10-Q · Aug 7, 2025 Risk: medium
  Coherus Oncology, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $116.2 million, up from $37.5 million in th
• Coherus Oncology Faces Delisting Concerns — 8-K · Jul 3, 2025 Risk: high
  Coherus Oncology, Inc. filed an 8-K on July 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effect
• Coherus Oncology Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025 Risk: low
  Coherus Oncology, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 11, 2025. The company, formerly kn
• Coherus Oncology Files 8-K with Corporate Updates — 8-K · May 30, 2025 Risk: low
  Coherus Oncology, Inc. filed an 8-K on May 29, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial
• Coherus BioSciences Q1 2025 10-Q Filed — 10-Q · May 12, 2025 Risk: low
  Coherus BioSciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported Selling, General & Administrative Expense of $37.5 million f
• Coherus BioSciences Files DEF 14A for Executive Compensation — DEF 14A · Apr 29, 2025 Risk: low
  Coherus BioSciences, Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity
• Coherus BioSciences CEO Departs, New Interim Officers Appointed — 8-K · Apr 25, 2025 Risk: medium
  Coherus BioSciences, Inc. announced on April 22, 2025, changes in its executive team and board. Specifically, Dennis M. Lanfear has departed as Chief Executive
• Coherus BioSciences Director Departs, Officer Compensation Noted — 8-K · Apr 22, 2025 Risk: low
  Coherus BioSciences, Inc. announced on April 16, 2025, a change in its board of directors. Specifically, Dennis M. Lanfear has departed from his role as a direc
• Coherus BioSciences Completes Asset Acquisition — 8-K · Apr 14, 2025 Risk: medium
  On April 11, 2025, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets from Organon & Co. This transaction involves the tran
• Coherus BioSciences Files 8-K with Material Agreement — 8-K · Apr 1, 2025 Risk: medium
  On March 31, 2025, Coherus BioSciences, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• Coherus BioSciences Files 2024 10-K — 10-K · Mar 17, 2025 Risk: medium
  Coherus BioSciences, Inc. filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing de
• Coherus BioSciences Files 8-K on Security Holder Vote — 8-K · Mar 13, 2025 Risk: low
  On March 11, 2025, Coherus BioSciences, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not pro
• Coherus BioSciences Files 8-K on Financials — 8-K · Mar 10, 2025 Risk: low
  Coherus BioSciences, Inc. filed an 8-K on March 10, 2025, reporting on its results of operations and financial condition, as well as filing financial statements
• Coherus BioSciences Relocates Principal Executive Offices — 8-K · Mar 4, 2025 Risk: low
  On March 4, 2025, Coherus BioSciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 333 Twin Dolphin
• Coherus BioSciences Files Definitive Proxy Statement — DEFA14A · Jan 30, 2025 Risk: low
  Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on January 30, 2025, related to its annual meeting. The filing concerns the solicitation
• Coherus BioSciences Files Proxy Statement — DEFA14A · Jan 14, 2025 Risk: low
  Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on January 14, 2025. This filing is related to the company's annual meeting and likely co
• Coherus BioSciences Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Coherus BioSciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Coherus BioSciences Files Definitive Proxy Statement — DEFA14A · Dec 4, 2024 Risk: low
  Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 4, 2024. This filing is related to the company's proxy materials, which are t
• Coherus BioSciences Announces CEO Change and Board Refresh — 8-K · Dec 4, 2024 Risk: medium
  On November 27, 2024, Coherus BioSciences, Inc. announced changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has stepped down
• Coherus BioSciences Enters Material Definitive Agreement — 8-K · Dec 3, 2024 Risk: medium
  On December 2, 2024, Coherus BioSciences, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement or a
• SC 13G Filing — SC 13G · Nov 13, 2024
• Coherus BioSciences Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Coherus BioSciences, Inc. filed its Q3 2024 10-Q report on November 6, 2024, for the period ending September 30, 2024. The company, formerly known as BioGeneric
• Daiichi Sankyo to Acquire Coherus BioSciences for $2 Billion — 8-K · Sep 13, 2024 Risk: medium
  On September 13, 2024, Coherus BioSciences, Inc. announced a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company, Limited. The transac
• Coherus BioSciences Q2 2024 10-Q: SG&A Expenses Detailed — 10-Q · Aug 8, 2024 Risk: medium
  Coherus BioSciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported Selling, General & Administrative Expense of $112.2 million f
• SC 13G/A Filing — SC 13G/A · Jul 23, 2024
• Coherus BioSciences Enters Material Definitive Agreement — 8-K · Jul 2, 2024 Risk: medium
  On June 27, 2024, Coherus BioSciences, Inc. entered into a Material Definitive Agreement. This agreement is related to the company's operations and is a signifi
• Coherus BioSciences Acquires Pfizer's Hulio Rights — 8-K · Jun 27, 2024 Risk: medium
  On June 26, 2024, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets from Pfizer Inc., specifically related to the U.S. com
• Coherus BioSciences Announces Executive and Board Changes — 8-K · Jun 5, 2024 Risk: medium
  Coherus BioSciences, Inc. announced on May 31, 2024, changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has departed as CEO a
• Coherus BioSciences Reports on Shareholder Vote Matters — 8-K · Jun 4, 2024 Risk: low
  Coherus BioSciences, Inc. filed an 8-K on June 4, 2024, reporting on matters submitted to a vote of security holders on May 29, 2024. The filing details the com
• SC 13G/A Filing — SC 13G/A · May 22, 2024
• Coherus BioSciences Files 8-K/A Amendment — 8-K/A · May 21, 2024 Risk: low
  Coherus BioSciences, Inc. filed an 8-K/A on May 21, 2024, to amend a previous filing regarding financial statements and exhibits. The original event date report
• Coherus BioSciences Files Definitive Proxy Statement — DEFA14A · May 13, 2024 Risk: low
  Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on May 13, 2024. This filing is related to the company's proxy materials, which are typic
• Coherus BioSciences Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Coherus BioSciences, Inc. (CHRS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Coherus BioSciences reported financial results for the quarter end
• Coherus BioSciences Files Definitive Proxy Statement — DEF 14A · Apr 15, 2024 Risk:
  Coherus BioSciences, Inc. (CHRS) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Coherus BioSciences, Inc. filed a Definitive Proxy Statement
• Coherus BioSciences Files 2023 Annual Report on Form 10-K — 10-K · Mar 15, 2024 Risk: medium
  Coherus BioSciences, Inc. (CHRS) filed a Annual Report (10-K) with the SEC on March 15, 2024. Coherus BioSciences, Inc. filed its 2023 Form 10-K on March 15, 20
• Coherus BioSciences Files 8-K on Financials — 8-K · Mar 13, 2024 Risk: low
  On March 13, 2024, Coherus BioSciences, Inc. filed an 8-K report detailing its financial results and operations. The filing includes information on the company'
• Coherus BioSciences Completes Pfizer Biosimilar Asset Acquisition — 8-K · Mar 4, 2024 Risk: medium
  On March 1, 2024, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets related to the U.S. commercialization of biosimilar pr
• Coherus BioSciences Reports Officer/Director Changes & Compensation — 8-K · Feb 22, 2024 Risk: medium
  Coherus BioSciences, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, specifical
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Coherus BioSciences Files 8-K on Material Agreement, Lacks Details — 8-K · Feb 5, 2024
  Coherus BioSciences, Inc. filed an 8-K on February 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the
• BlackRock Amends Coherus BioSciences Stake as of Dec 31, 2023 — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of Coherus BioSciences Inc. common stock as of December 31, 2
• Coherus BioSciences Reports Material Definitive Agreement — 8-K · Jan 22, 2024
  Coherus BioSciences, Inc. filed an 8-K on January 22, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 19, 2024. While t
• State Street Corp Updates Passive Stake in Coherus BioSciences — SC 13G/A · Jan 22, 2024
  State Street Corp, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Coherus BioSciences, Inc. common st
• Coherus BioSciences Files Routine 8-K on Corporate Details — 8-K · Jan 10, 2024
  This 8-K filing from Coherus BioSciences, Inc. (CHRS) on January 10, 2024, is a routine administrative filing, specifically an "Other Events" report. It confirm

Related Companies

CPRX · DSNKY · PFE

Frequently Asked Questions